Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (5768)	12/15/1998 12:23:00 PM
From: scaram(o)uche	Respond to of 6136

TD: Joe nailed it, IMO. I feel that the target is prophylaxis of high risk populations. Long term? Let's see what the toxicity profiles look like. I don't get them frequently, but colds hit me hard, and the sequelae make me miserable. I'd love something that would take the hard edge off of an occasional rhino encounter. Small market initially (if and when!!), but the patent has a long, long run. :-) Yes, companies like Bayer (Miles) were chasing rhino for ages, but..... wrong target, IMO.

To: Joe E. who wrote (5768)	12/15/1998 12:34:00 PM
From: sam	Read Replies (2) \| Respond to of 6136

Isn't "curing the common cold" one of those ambitions we used to believe were impossible (like bringing peace to the Middle East or eradicating world hunger)? I think it will be worth at least a 1 or 2 point pop on the initial news release. Kidding of course. Particularly since AGPH's stock has performed remarkably well during the last few months. No complaint here. With the stock or the company. FWIW, price (in addition to the drug's profile) may also be a factor in its widespread acceptance.